The ACIP recommends preexposure vaccination with rVSV-ZEBOV for adults aged 18 years of age and older in the US who are at high risk of occupational exposure to Ebola because they are doing the following: Responding to an outbreak of Ebola virus disease Working as health care personnel at federally designated Ebola treatment centers in the US Working as laboratory personnel or as other staff at biosafety level 4 facilities in the US Working as laboratory personnel or support staff members at Laboratory Response Network facilities Ad26.ZEBOV / MVA-BN-Filo is indicated for the prevention of Ebola virus disease caused by the Zaire ebolavirus species in people aged 1 year of age and older.